Celixir company
Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchers to discover breakthrough medicines that aim to change the standard of medical care for patients.
Technology:
P4 Medicine
Headquarters:
Cardiff, Cardiff, United Kingdom
Total Funding:
$2.6M
Investment Stage:
N/A
Last Funding Type:
Venture - Series Unknown
Number Of Exists:
Venture - Series Unknown
Founded Date:
Undisclosed
Investors Number:
1
Industry:
Regenerative Medicine
Employee Number:
11-50
Investor Type:
Company
Funding Status:
M&A